Orogen Therapeutics Selects Two Development Candidates for Immune Diseases, Targeting IL-17 and JAK1/TYK2

Orogen Therapeutics Selects ORO-110 and ORO-210 Development Candidates for Inflammatory Diseases Orogen Therapeutics, Inc. (“Orogen” or the “Company”) announced the selection of two development candidates, ORO-110 and ORO-210, as potential…

Read MoreOrogen Therapeutics Selects Two Development Candidates for Immune Diseases, Targeting IL-17 and JAK1/TYK2

Roquette Showcases Comprehensive Excipient Solutions and Technical Expertise at AAPS PharmSci 360 2026

Roquette to Showcase Advanced Pharmaceutical Excipients and Drug Delivery Innovations at AAPS PharmSci 360 2026 Roquette, a global leader in plant-based ingredients, pharmaceutical excipients and specialized pharmaceutical solutions, will present…

Read MoreRoquette Showcases Comprehensive Excipient Solutions and Technical Expertise at AAPS PharmSci 360 2026

Independent Assessment Finds BrightFocus Foundation’s $330M+ Investment in High-Risk Science Delivering Results

BrightFocus Foundation’s $330 Million Research Investment Generates Eightfold Increase in Follow-On Funding, Assessment Finds BrightFocus Foundation, a nonprofit organization dedicated to advancing research into Alzheimer’s disease, macular degeneration, and glaucoma,…

Read MoreIndependent Assessment Finds BrightFocus Foundation’s $330M+ Investment in High-Risk Science Delivering Results